ⅢC～Ⅳ期上皮性卵巢癌预后影响因素分析

目的:探讨ⅢC～Ⅳ期上皮性卵巢癌患者预后的影响因素,为临床诊疗提供数据支持。方法:回顾分析广西医科大学附属肿瘤医院129例ⅢC～Ⅳ期上皮性卵巢癌患者的临床资料,包括年龄、临床分期、组织病理学类型与分级、手术残余病灶直径和术后化疗周期数等。分析评价各因素对ⅢC～Ⅳ期上皮性卵巢癌预后的影响。结果:单因素分析显示,年龄、手术残余病灶直径、术后化疗周期数与患者预后密切相关,临床分期、病理学类型与组织学分级对预后无显著影响。应用COX回归模型进行多因素分析,患者年龄≥50岁(RR=0.493,95%CI:0.308～0.790)、手术残余病灶直径≥1 cm(RR=2.527,95%CI:1.585～4.028)及术后化疗周期数6次(RR=2.294,95%CI:1.464～3.593)为ⅢC～Ⅳ期上皮性卵巢癌患者预后的独立危险因素。结论:对于ⅢC～Ⅳ期上皮性卵巢癌患者,年龄越大、手术残余病灶直径越大、术后化疗周期数越少,预后越差。     

56例复发性卵巢癌无瘤生存期影响因素及治疗后预后分析

目的:探讨复发性卵巢癌患者无瘤生存期(DFI)相关影响因素并分析两种治疗方案患者的生存预后。方法:回顾性分析56例复发性卵巢癌患者临床资料。按复发后治疗方法不同分为二次肿瘤细胞减灭术联合术后化疗22例(手术组),单纯化疗34例(化疗组)。结果:1病理类型、组织学分级、临床分期、初次术后化疗疗程数及初次术后残余病灶大小与患者DFI有关(P0.05),年龄与DFI无关(P0.05);多因素分析提示临床分期、初次术后残余病灶大小是DFI独立影响因素,临床分期越早、初次术后残余病灶越小,DFI越长。2手术组较化疗组复发后中位生存时间明显延长,分别为30月与16月(χ~2=10.849,P=0.010)。复发后化疗组1、2、3、4年生存率分别为65%,32%,8%,0,手术组分别为95%,75%,29%,0;手术组复发后生存率较化疗组高,差异有统计学意义(P0.05)。结论:复发性卵巢癌患者DFI与病理类型、组织学分级、临床分期、初次术后化疗疗程数及初次术后残余病灶大小相关,临床分期、初次术后残余病灶大小是DFI的独立影响因素。二次肿瘤细胞减灭术联合化疗可提高患者复发后的近期生存率。     

卵巢上皮性癌雌激素受体、孕激素受体和P53的表达与其预后的关系

目的:探讨卵巢上皮性癌雌激素受体(ER)、孕激素受体(PR)和P53蛋白的表达特点及与生存时间的关系。方法:应用免疫组化法检测70例卵巢上皮性癌组织ER、PR和P53阳性表达情况,分析其与临床病理特征的关系,并对其与生存率的关系进行单因素及多因素分析。结果:①70例卵巢上皮性癌组织中,ER表达阳性29例(41.4%),PR表达阳性30例(42.9%),P53蛋白表达阳性41例(58.6%)。PR阳性表达在年龄、月经状态和组织学类型的比较中,差异有统计学意义(P=0.027;P=0.025;P=0.005)。ER和P53阳性表达在各项临床病理特征的比较中,差异均无统计学意义(P0.05)。②单因素分析显示,不同年龄、残余肿瘤灶直径、FIGO分期、组织学分级和PR阳性表达患者的3年生存率分别比较,差异均有统计学意义(P0.05)。③多因素分析显示,残余肿瘤灶直径是影响生存率的独立危险因素(RR 5.058,95%CI 1.658~15.434),而PR则是独立的保护因素(RR 0.254,95%CI 0.071~0.909)。结论:年轻、未绝经、浆液性癌患者的PR阳性表达比例明显增高,PR阳性表达是卵巢上皮性癌独立的保护因素。ER和P53蛋白表达不是影响卵巢上皮性癌生存率的重要因素。     

脾切除术治疗卵巢上皮性癌脾转移32例临床分析

目的 探讨卵巢上皮性癌(卵巢癌)脾转移的临床病理特点,分析脾切除术作为卵巢癌肿瘤细胞减灭术的一部分的可行性及预后因素.方法 采用回顾性研究方法,收集1998年1月至2006年6月在浙江省肿瘤医院行包括脾切除的肿瘤细胞减灭术的32例卵巢癌患者,对其临床病理及随访资料进行分析.结果 浆液性腺癌为23例(72%),9例(28%)为非浆液性腺癌;病理分级:G1 0例,G2 11例(34%),G3 21例(66%).术后20例无肉眼可见残余肿瘤,7例残余肿瘤直径≤2 cm,5例残余肿瘤直径＞2 cm.手术并发症发生率为25%(8/32),包括脾窝脓肿、腹壁切口感染、胃瘘、应激性胃溃疡、静脉血栓、不全肠梗阻等.中位随访时间为38个月(1～74个月),中位生存时间为50.9个月,2年、5年生存率分别为70%、36%.单因素分析显示病理分级、残余肿瘤有无、化疗疗程数影响预后(P均＜0.05);多因素分析显示,仅残余肿瘤有无及化疗疗程数与预后有关(P均＜0.05).结论 卵巢癌脾转移最常见的病理类型为低分化浆液性腺癌.对于卵巢癌脾转移患者,脾切除术作为肿瘤细胞减灭术的一部分是安全、有效的治疗方法;术后残余肿瘤有无、化疗疗程数是独立的预后因素.     

ⅢC~Ⅳ期上皮性卵巢癌预后影响因素分析

目的：探讨ⅢC~Ⅳ期上皮性卵巢癌患者预后的影响因素,为临床诊疗提供数据支持。方法：回顾分析广西医科大学附属肿瘤医院129例ⅢC~Ⅳ期上皮性卵巢癌患者的临床资料,包括年龄、临床分期、组织病理学类型与分级、手术残余病灶直径和术后化疗周期数等。分析评价各因素对ⅢC~Ⅳ期上皮性卵巢癌预后的影响。结果：单因素分析显示,年龄、手术残余病灶直径、术后化疗周期数与患者预后密切相关,临床分期、病理学类型与组织学分级对预后无显著影响。应用COX回归模型进行多因素分析,患者年龄≥50岁（RR=0.493,95%CI：0.308～0.790）、手术残余病灶直径≥1 cm（RR=2.527,95%CI：1.585～4.028）及术后化疗周期数＜6次（RR=2.294,95% CI：1.464～3.593）为ⅢC~Ⅳ期上皮性卵巢癌患者预后的独立危险因素。结论：对于ⅢC~Ⅳ期上皮性卵巢癌患者,年龄越大、手术残余病灶直径越大、术后化疗周期数越少,预后越差。     

卵巢上皮性癌的预后影响因素分析

目的 探讨卵巢上皮性癌(卵巢癌)的预后影响因素.方法 回顾性分析2002年1月至2005年12月在山西省肿瘤医院初诊的卵巢癌患者的临床病理资料.结果年龄、分期、病理类型、病理分化程度、术后残余瘤的大小以及术后化疗疗程数是卵巢癌的预后因素(P<0.01).以Ⅳ期患者的死亡风险为1,则Ⅰ期、Ⅱ期、Ⅲ期患者的死亡风险分别为0.005、0.106、0.361,95% CI分别为0.001～0.024、0.038～0.297、0.181～0.718(P<0.01);以术后残余瘤直径>2 cm患者的死亡风险为1,则残余瘤直径≤2 cm患者的死亡风险仅为0.307,95% CI为0.176～0.536(P<0.01);术后化疗疗程数<6个疗程患者的死亡风险为≥6个疗程者的8.191倍,95% CI为4.666～14.379(P<0.01).是否有恶性肿瘤家族史对卵巢癌预后无影响(P>0.05).结论 分期、术后残余瘤的大小、术后化疗的疗程数是卵巢痛的独立预后影响因素.尽力做到早诊断、早治疗,术后辅以正规、足疗程的化疗是提高卵巢癌生存率的关键.     

外周血循环肿瘤细胞对卵巢癌患者临床病理特征和预后关系的Meta分析

目的:系统性评价外周血循环肿瘤细胞(CTCs)与卵巢癌患者的相关临床病理特征及其预后的相关性。方法:计算机检索PubMed、EMbase、Cochrane图书馆、CNKI及CBM等数据库,收集循环肿瘤细胞(CTCs)与卵巢癌患者预后的相关研究。检索时间从建库至2019年5月30日。由2位独立研究者按纳入及排除标准筛选文献、提取数据以及质量评价等,使用RevMan5.3软件进行Meta分析。结果:共纳入13篇文献。Meta分析结果示,CTCs阳性组与卵巢肿瘤分期(RR=0.54,95%CI为0.31～0.95)及肿瘤分级均呈正相关(RR=0.76,95%CI为0.59～0.98),与肿瘤细胞病理类型无相关性(RR=1.00,95%CI为0.74～1.33)。CTCs阳性组与CTCs阴性组的OS(HR=1.56,95%CI为1.25～1.95)和PFS(HR=1.43,95%CI为1.18～1.75)比较,差异均有统计学意义,提示CTCs阳性组患者的预后差。结论:CTCs可能在卵巢癌患者疾病进展过程中起重要作用,外周血CTCs阳性是卵巢癌患者不良预后的重要危险因素,有望应用于临床成为评估卵巢癌预后的指标。     

初始治疗结束后血清视黄醇结合蛋白水平与卵巢癌预后关系研究

目的探讨初始治疗结束后血清视黄醇结合蛋白(RBP)表达水平与卵巢癌预后的关系。方法收集2015年4月至2019年3月辽宁省肿瘤医院初始治疗结束后并达到临床完全缓解的126例卵巢癌患者。以初始治疗结束后血清RBP表达水平25mg/L为阈值,将患者分为高水平组(RBP≥25mg/L)65例和低水平组(RBP 25mg/L) 61例。对两组患者的无进展生存期(PFS)进行比较,并通过单因素和多因素分析确定卵巢癌预后的风险因素。结果Kaplan-Meier分析显示:初始治疗结束后血清RBP水平减低的患者PFS较长[低水平组(28.6±4.8)个月vs.高水平组(15.4±4.7)个月],差异有统计学意义(P 0.05)。多因素Cox分析显示:初始治疗结束后血清RBP水平25mg/L(HR 0.33,95%CI 0.172～0.654,P=0.041)、病理分期(HR 2.15,95%CI 1.42～0.3.31,P=0.018)、分化程度(HR1.52,95%CI 1.132～1.875,P=0.036)、淋巴结转移(HR 1.41,95%CI 1.251～1.926,P=0.043)是影响卵巢癌预后的独立因素。结论初始治疗结束后血清RBP水平、病理分期、分化程度和淋巴结转移是卵巢癌患者预后的独立影响因素。     

子宫颈癌肺转移患者的临床特征及预后影响因素分析

目的:探讨子宫颈癌肺转移患者的临床特征及预后影响因素。方法:回顾性分析2017年1月至2022年1月郑州大学第一附属医院收治的65例子宫颈癌肺转移患者的临床资料，分析其临床病理特征、治疗及3年预后的影响因素。结果:65例患者中，仅8例(12.3%)患者以肺部症状就诊而发现肺转移。69.2%(45/65)患者肺转移发生在子宫颈癌治疗后2年内，肺转移灶多位于右肺下叶。发生肺转移后中位生存时间为19个月，2年和3年生存率分别为30.8%(20/65)和13.8%(9/65)。7例患者接受肺转移灶手术治疗，手术达完全切除。子宫颈癌的分化程度、病理类型、神经侵犯、淋巴结转移以及肺转移的范围与子宫颈癌肺转移患者的3年预后有关(P<0.05),其中子宫颈癌的分化程度(RR 11.248,95%CI 1.076～117.597)和肺转移范围(RR 9.546,95%CI 1.024～88.955)是子宫颈癌肺转移患者3年预后的独立影响因素(P<0.05)。结论:子宫颈癌肺转移临床症状较隐蔽，子宫颈癌患者治疗结束后1～2年应严格随访，定期行肺部影像学检查，争取做到早期诊断、早期治疗。分化程度...     

子宫内膜癌126例临床病理与预后分析

目的:探讨子宫内膜癌的临床、病理特点及影响预后的因素。方法:回顾分析了2000年1月至2004年12月5年间山东大学齐鲁医院收治的126例子宫内膜癌患者的临床资料。结果:126例子宫内膜癌患者平均发病年龄53.5岁,获得随访的113例患者3年生存率为85.7%,5年生存率为75.1%,总体生存率为69.7%。多因素分析结果显示,手术病理分期(P=0.009)、组织学分级(P=0.006)、淋巴结转移(P=0.025)、病理类型(P=0.001)与预后显著相关,是影响子宫内膜癌患者总体生存率的独立因素。结论:子宫内膜癌手术病理分期、组织学分级、淋巴结转移、病理类型和预后有显著相关性,是影响患者总体生存率的独立因素。     

卵巢上皮性癌的腹膜后淋巴结切除对预后的影响

目的　探讨卵巢上皮性癌患者腹膜后淋巴结切除对预后的影响。方法　回顾性分析13 1例卵巢上皮性癌患者的临床资料 ,应用COX风险比例回归模型判断影响预后的因素。结果　多因素分析显示 ,年龄、临床分期、残留灶、腹膜后淋巴结切除术及术后化学药物治疗 (化疗 ) ,是影响预后的重要因素。行和未行腹膜后淋巴结切除术患者的 5年生存率分别为 66%和 41% (P <0 0 1)。对于早期和Ⅲ、Ⅳ期肿瘤残留灶直径 >2cm或黏液性癌患者 ,腹膜后淋巴结切除术并不能提高生存率。Ⅲ、Ⅳ期肿瘤残留灶直径≤ 2cm ,行与未行腹膜后淋巴结切除术患者的 5年生存率分别为 65 %、3 0 %(P <0 0 1)。卵巢浆液性癌 ,行与未行腹膜后淋巴结切除术患者的 5年生存率分别为 61%、3 1% (P<0 0 1)。结论　年龄、临床分期、残留灶大小、腹膜后淋巴结切除与否及术后化疗的疗程数 ,与卵巢上皮性癌患者的预后有关。腹膜后淋巴结切除术虽能提高患者生存率 ,但对肿瘤残留灶直径 >2cm的Ⅲ、Ⅳ期卵巢上皮性癌患者 ,可不必行腹膜后淋巴结切除术     

晚期卵巢上皮性癌的治疗及其对预后的影响

目的:探讨晚期卵巢上皮性癌的治疗及其对预后的影响。方法:回顾分析晚期卵巢上皮性癌患者76例的临床资料,生命统计采用Kaplan-Meier法及Log-rank法检验,利用COX风险比例回归模型判断患者独立的预后影响因素并进行分析。结果:分期、残余灶、腹膜后淋巴结清除术及术后化疗的疗程数是影响预后的重要因素。行和未行腹膜后淋巴结清除术,总的5年存活率分别是52％和22％(P<0.01)。其中残余灶≤2cm者,行与未行腹膜后淋巴结清除术的5年存活率分别是65％、30％(P<0.01)。残余灶>2cm者,行与未行腹膜后淋巴结清除术的5年存活率分别是21％、9％,但差异没有显著性(P>0.05)。结论:理想的肿瘤细胞减灭术、腹膜后淋巴结清除术及术后至少6个疗程的化疗是改善患者预后的重要措施,但如残余灶>2cm,则不必行腹膜后淋巴结清除术。     

Patients with advanced ovarian cancer after negative second-look laparoscopy--follow up study

OBJECTIVES: Follow-up in 65 patients with stage III-IV ovarian cancer after negative second-look laparotomy. Prognostic factors and causes of failure were also discussed. MATERIAL AND METHODS: 65 patients with ovarian cancer stage III-IV were treated with surgery and at least six courses of chemotherapy (cisplatin, adriamycin, cyclophosphamide) and second-look laparotomy. Results of the treatment are presented in a form of 5-year NED (no evidence of disease) survival. Dependence between analyzed factors and survival was assessment based on proportional hazard Cox model. RESULTS: In 30 patients (46.1%) recurrence during 5 year follow-up was observed. In 28 patients out of them (93.3%) it was loco-regional failure and in 2 patients distant metastases were the sole reason of unsuccessful results of the treatment. Adverse prognostic factors found in statistical analysis were: advanced primary stage, residual infiltrations after first laparotomy exceeding 2 cm and low grade of differentiation. CONCLUSIONS: 1. In about 50% of patient with advanced ovarian cancer loco-regional recurrence was observed, 2. Adverse prognostic factors were: advanced primary stage, residual masses after first laparotomy above 2 cm and low grade of differentiation.     

晚期卵巢上皮性癌的预后变化及影响因素分析

目的：了解近２０余年晚期卵巢上皮性癌的预后有无改善，及影响预后的因素。方法：对１９７０年至１９９３年在我院住院治疗的１４０例晚期卵巢上皮性癌病例进行分析，按患者的初治时间分为两组，１９８０年１月以前的５６例为第１组，之后的８４例为第２组，计算两组的Ｋａｐｌａｎ－Ｍｅｉｅｒ生存率曲线，用ＳＰＳＳ及ＳＵＲＶＣＡＬＣ统计软件对资料进行单因素及ＣＯＸ逐步回归分析，确定影响患者预后的因素。结果：两组的病理资料无差异，但第２组得到了更积极的化疗。总的１年、２年及５年生存率分别为６１．２％、３２．１％和８．５％，第１组分别为４２．３％、２９．６％和４．５％，第２组分别为６９．３％、３６．２％和１１．２％，第２组预后好于第１组（Ｐ＜０．０５）。临床分期晚、分化差、残余瘤直径＞２ｃｍ者预后差。联合化疗≥４个疗程者预后改善，≥６个疗程者又较≥４个疗程者预后好。结论：晚期卵巢上皮性癌的预后近１０余年来有所改善，提高肿瘤细胞减灭术的彻底性及行至少６个疗程的联合化疗是改善预后的重要措施。     

Prognostic factors in early-onset epithelial ovarian cancer: a population-based study

OBJECTIVE: To investigate the clinical prognostic factors that influence ovarian cancer survival in women with early-onset epithelial ovarian cancer using population-based data. METHODS: Subjects in the current study were from a population-based series of 197 patients with invasive ovarian cancer and 60 patients with ovarian cancer of low malignant potential who were identified from the Cancer and Steroid Hormone study. All subjects were between 20 and 54 years of age at diagnosis for ovarian cancer. Epidemiologic data were obtained from each participant. Immunohistochemical staining was performed to assess p53 expression in paraffin-embedded ovarian cancers. Univariate and multivariate analyses for survival were conducted using the proportional hazards model to test the prognostic significance of several clinicopathologic factors among subjects. RESULTS: Among women with invasive tumors, the proportional hazards model revealed that advanced stage at diagnosis [hazard ratio = 4.1, 95% confidence interval (CI) = 2.5, 6.6], age at diagnosis 46-54 (hazard ratio = 2.0, 95% CI = 1.3, 3.0), and overexpression of p53 (hazard ratio = 1.5, 95% CI = 1.1, 2.3) were significantly associated with decreased survival. CONCLUSION: These results provide evidence that stage, age, and p53 overexpression are independent predictors of decreased survival in women with invasive ovarian cancer diagnosed younger than age 55. Further investigation of the effect of age at diagnosis on the relationship between p53 overexpression and ovarian cancer survival is warranted.     

Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients

OBJECTIVE: To evaluate the prognostic significance of and predictive value for survival of CA 125 and TPS levels after three chemotherapy courses in ovarian cancer patients. METHODS: We analyzed in a prospective multicenter study the 1- and 2-year overall survival (OS) in ovarian carcinoma patients. The prognostic significance of CA 125 and TPS levels above the discrimination value (25 kU/L and 100 U/L, respectively) was examined by univariate and multivariate analyses. RESULTS: Of the 213 cases included, 64 patients were staged as FIGO I + II and 149 patients were staged as FIGO III + IV. Tumor marker levels in stage I + II were not correlated with survival. However, stage III and IV patients with elevated levels of CA 125 or TPS after three chemotherapy courses had a worse 2-year OS (69% vs 26%, P < 0.0001 and 57% vs 20%, P < 0.0001, respectively) than patients with normal levels of the markers. In univariate analysis the result of operation (staging laparatomy and partial debulking) and advanced FIGO stage (IV) were also adverse prognostic factors. Independent factors predictive of low 2-year OS by multivariate analysis were staging laparotomy, TPS elevated, and CA 125 elevated. The only factors predictive of low 1-year OS were TPS elevated and staging laparotomy. CONCLUSIONS: Ovarian cancer patients with elevated CA 125 levels after three chemotherapy courses have a poor prognosis. However, the prognostic accuracy can be significantly increased by the parallel determination of serum TPS.     

Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study

OBJECTIVE: In the present study, we conducted a multicenter retrospective analysis to elucidate the prognostic factors of stage IV epithelial ovarian cancer. METHODS: In November 1999, 24 Japanese institutions received questionnaires regarding stage IV epithelial ovarian cancer patients. Eligibility criteria included all patients with stage IV epithelial ovarian cancer who were surgically confirmed and initially treated in each institution between January 1990 and December 1997. Data were collected regarding age, performance status, tumor histologic subtype, site of metastasis, preoperative CA125, cytoreductive surgery, residual disease after cytoreductive surgery, and response to primary chemotherapy. Survival analysis and comparisons were performed by univariate and multivariate methods. RESULTS: Two hundred twenty-five patients with stage IV ovarian cancer were identified. The median age of the patients was 54 years. The most common site of extraperitoneal disease was malignant pleural effusion (39.6%). Of the 225 patients who underwent an attempt at surgical debulking, 70 (31.1%) were optimally cytoreduced. Most patients received platinum-based combination chemotherapy for primary chemotherapy. In multivariate analysis, performance status, histology, and residual disease after cytoreductive surgery were independent prognostic predictors of outcome. The overall median survival for optimally debulked patients was 32 months compared to 16 months for suboptimally debulked patients (P < 0.0001, hazard ratio: 0.415). CONCLUSION: Optimal surgical debulking, performance status, and histology appear to be important prognostic factors of survival in patients with stage IV epithelial ovarian cancer.     

血清胆固醇水平对宫颈癌患者预后的影响

目的:探讨治疗前血清胆固醇水平对宫颈癌患者预后的影响。方法:回顾分析2016年1月1日至2016年12月31日四川省肿瘤医院妇科肿瘤中心收治的277例宫颈癌患者的临床病理资料和随访记录。绘制ROC曲线,评价治疗前血清胆固醇对患者预后的预测效果。分析患者临床病理资料与血清胆固醇水平的关系。应用Kaplan-Meier法绘制生存曲线,建立Cox比例风险模型分析患者预后影响因素。结果:血清胆固醇水平预测DFS、OS的临界值分别为4.875mmol/L、4.605mmol/L。Cox比例风险模型单因素及多因素分析显示,治疗前血清胆固醇水平是影响宫颈癌患者DFS及OS的危险因素。结论:治疗前血清胆固醇水平可作为宫颈癌患者预后风险评价指标。     

卵巢交界性上皮性肿瘤的预后分析

目的:探讨卵巢交界性上皮性肿瘤影响预后的因素。方法:回顾分析71例卵巢交界性上皮性肿瘤患者的临床资料,采用单因素和多因素分析方法分析影响复发和预后的因素。结果:BOT患者的5年总生存率97.0%,5年无瘤生存率为94.0%。单因素分析发现,FIGO分期、微浸润、腹膜种植、手术切除类型(肿瘤剥除与附件切除)、肿瘤包膜破裂、双侧卵巢受累与卵巢交界性肿瘤的预后有关(P0.05)。COX多因素模型分析提示,手术切除类型、肿瘤包膜破裂是影响预后的独立因素(P0.05)。结论:BOT发病年龄轻,预后良好,其复发与肿瘤FIGO分期、微浸润、腹膜种植、手术切除类型、包膜破裂等相关。对有高危因素者术后需长期密切随访。     

Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer

OBJECTIVE: It is well known that the serum level of Interleukin-6 (IL-6) correlates with the level of C-reactive protein (CRP). The purpose of this study is to determine the significance of CRP as a prognostic factor in epithelial ovarian cancer. STUDY DESIGN: The present study is comprised of 120 patients with epithelial ovarian cancer from 1985 to 1992. In this study, CRP levels above 50 mg/l were considered high CRP. Univariate and multivariate analyses were performed to identify clinicopathological variables associated with poor survival. RESULTS: The serum CRP value was significantly associated with the volume of ascites (P = 0.000004). Univariate analysis showed that the FIGO stage, primary tumour diameter, size of residual tumour, histologic grade, volume of ascites and high serum level of CRP were significant prognostic factors. Cox's multivariate proportional hazard model showed that histologic grade was the most important prognostic factor (P = 0.0026). FIGO stage and volume of ascites were also independent factors for 5-year survival (P = 0.0310 and P = 0.0216, respectively). However, the serum CRP value was not an independent prognostic factor. CONCLUSION: CRP is an adverse prognostic factor in univariate analysis, but not in multivariate analysis.